Gene transfer into B-cells by lentivectors can provide an alternative approach to managing B lymphocyte malignancies and autoreactive B-cell-mediated autoimmune diseases. These pathogenic B-cell populations can be distinguished by their surface expression of monospecific-immunoglobulin. Development of a novel vector system to deliver genes to these specific B-cells could improve the safety and efficacy of gene therapy. We have developed an efficient method to target lentivectors to monospecific immunoglobulin-expressing cells in vitro and in vivo. We were able to incorporate a model antigen CD20 and a fusogenic protein derived from the Sindbis virus as two distinct molecules into the lentiviral surface. This engineered vector could specifically bind to cells expressing surface immunoglobulin recognizing CD20 ( CD20), resulting in efficient transduction of target cells in a cognate antigen-dependent manner in vitro, and in vivo in a xenograted tumor model. Tumor suppression was observed in vivo using the engineered lentivector to deliver a suicide gene to a xenografted tumor expressing CD20. These results show the feasibility of engineering lentivectors to target immunoglobulin-specific cells to deliver a therapeutic effect. Such targeting lentivectors also could potentially be used to genetically mark antigen-specific B-cells in vivo to study their B-cell biology.
Introduction
5 cells via CD20 (Yang et al., 2006) . The method involves the incorporation of a surface antibody specific to CD20 and a fusogenic protein as two distinct molecules into the lentiviral surface. We have shown that this targeting method allows for efficient and specific delivery of genes to human B-cells in vitro and in vivo (Yang et al., 2006) . In this report, we engineer lentivectors capable of specifically transducing immunoglobulinspecific cells. Using CD20 surface immunoglobulin as a model target, we demonstrate that targeting lentivectors displaying a cognate antigen and a fuosgenic protein can deliver genes to cells expressing specific surface immunoglobulin both in vitro and in vivo with remarkable specificity and efficiency. This result also expands our targeting methodology and presents a first example of targeting lentivectors to immunoglobulinspecific cells.
Materials and Methods
Mice NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME) were maintained in the university's animal facility and cared for in accordance to institute regulations. Treated mice were maintained on the mixed antibiotic sulfamethoxazole and trimethoprim oral suspension (Hi-Tech Pharmacal, Amityville, NY).
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FACScan (Becton Dickinson, San Jose, CA) and analyzed using FlowJo software (Tree Star, Ashland, OR).
Lentivector plasmids
Lentivector plasmids used in this study are FUGW (Lois et al., 2002) , FUW, FUWLuc, and FUWSR39tk. FUW is a self-inactivating third generation lentivector. To make FUWLuc and FUWSR39tk firefly luciferase cDNA amplified from pGL4.12Luc2P (Promega, Madison, WI) or SR39tk (Black et al., 2001) respectively was cloned downstream of the human ubiquitin-C promoter in the lentivector plasmid FUW.
Viral vector production
Human CD20 cDNA was cloned downstream of the CMV promoter in pcDNA3 (Invitrogen, Carlsbad, CA) to create pCD20. Lentivectors were generated by calcium phosphate precipitation transfection of 293T. 293T were transfected with the appropriate lentivector plasmid (5 µg), together with 2.5 µg each of pCD20, pSINmu (Yang et al., 2006) and the packaging vector plasmids (pMDLg/pRRE and pRSV-Rev (Dull et al., 1998) ) when 80% confluent in 6-cm culture dishes. The viral supernatants were harvested 36 and 48 hours after transfection and filtered through a 0.45 µm pore size filter (Nalgene, Lima, OH). Titering was done by serial dilution of the virus on 293T or 293T/ CD20 cells with GFP expressing virus. FACS was used to determine the linear range of infection measured by GFP expression. For animal experiments, viral vectors were concentrated using ultracentrifugation described previously (Yang et al., 2006) .
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Cell line construction
To construct cell lines expressing CD20-specific surface immunoglobulin, we amplified the cDNAs of the light chain ( CD20L) and the heavy chain ( CD20H) of mouse/human chimeric antibody (clone 2H7) from plasmid p CD20 (Yang et al., 2006) and cloned them into FUW to generate FUW CD20L and FUW CD20H. The cDNAs of human Bcell co-receptor, Ig and Ig , were cloned into FUW to yield FUWIg and FUWIg .
VSVG-pseudotyped viruses were prepared for FUW CD20L, FUW CD20H, FUWIg and FUWIg . These viruses were used to co-transduce target cells. After a few passages, the resulting cells were stained by anti-human IgG1 antibody and subjected to cell sorting to obtain a uniform population of CD20 + cells designated 293T/ CD20 or Jurkat/ CD20. To make Jurkat/ CD20Luc FUWLuc was pseudotyped with VSVG and used to transduce Jurkat/ CD20.
Targeted transduction of cell lines in vitro
293T/ CD20, 293T, Jurkat/ CD20, or Jurkat cells (0.1×10 6 ) were plated with 2mL of viral supernatant in a 24-well tissue culture dish (BD Falcon TM , San Jose, CA). The cells and supernatant were incubated for 8 hours at 37°C, 5% CO 2 Then cells were cultured for 4 days in fresh media at 37°C, 5% CO 2 . The percentage of GFP + cells was determined by FACS.
8 an isotype control (IgG 2b , , BD Biosciences) or NH 4 Cl (Fisher Scientific, Waltham, MA). The media was replaced 8 hours later with fresh media and incubated for another 4 days at 37°C, 5% CO 2 . GFP expression was analyzed using FACS.
Imaging for virus and virus-cell binding
For labeling CD20 expression on the cell surface, 293T and 293T/ CD20 cells preincubated onto a 35mm glass-bottom culture dish (MatTek Corporation, Ashland, MA) were fixed with 4% formaldehyde and immunostained with AlexaFluor 594-labeled goat anti-human IgG (Invitrogen). These samples were also treated by DAPI nuclear staining.
For detection of individual viral particles fresh viral supernatants were overlaid upon poly-lysine coated coverslips and centrifuged at 3,700× g at 4°C for 2 hours. The coverslips were rinsed with cold PBS twice, and adhered viruses were immunostained with Alex-647 anti-human CD20 (Biolegend, San Diego, CA) and anti-HA-biotin (Miltenyi Biotec) followed by the secondary staining using Texas red-streptavidin (Zymed Laboratories, South San Fransico, CA). The coverslips were then mounted in Vectashield (Vector Laboratories, Burlingame, CA). For imaging virus-cell binding, 5x10 5 cells were seeded onto a 35mm glass-bottom culture dish and grown at 37°C
overnight. The seeded cells were rinsed with cold PBS twice and incubated with concentrated viruses for 1 hour at 4°C to allow binding but inhibit endocytosis. Cells were washed with cold PBS to remove unbound viruses, fixed and then imaged in PBS.
Fluorescent images were taken by a Zeiss LSM 510 laser scanning confocal microscope.
A plan-apochromat 63x/1.4 oil immersion objective was used for imaging. Images were analyzed with the use of Zeiss LSM image browser software.
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Targeted transduction of cell lines in vivo

Suicide gene delivery in vivo
Mice were anesthetized and injected on the right-flank subcutaneously with 5×10 6 Jurkat/ CD20Luc. Eight hours later the mice were injected subcutaneously with concentrated lentivectors at an MOI of 10 expressing Herpes Simplex Virus-1 Thymidine Kinase mutant SR39Tk (FUWSR39tk/CD20+SINmu or FUWSR39tk/VSVG) or no virus as a control on the right-flank . On days 7 through 12, mice were injected intraperitonially daily with 50 mg/kg of the prodrug ganciclovir (GCV; Sigma Aldrich,
St. Louis, MO).
To analyze the tumor size, mice were imaged using a Xenogen IVIS 200 as described above. This experiment was performed in triplicate.
The two necessary functions of the lentiviral envelope protein are binding to the host cell and fusion of the viral membrane with the cell's membrane to release the contents of the lentivirus into the cytoplasm (Dimitrov, 2004) . By separating these functions into two separate proteins on a gamma-retroviral or lentiviral surface, cellspecific targeting can be achieved while maintaining viral titers (Lin et al., 2001; Chandrashekran et al., 2004; Yang et al., 2006) . There are several features to consider in order to create an effective targeting lentiviral particle using this strategy. First, the binding of the lentivectors to the cell should induce endocytosis, and must not interfere with fusion. Second, the fusion molecule should be incorporated into the surface of the lentivector, should not interfere with binding, and should induce fusion at low pH. We set out to test if this general method could be extended to target B-cells expressing a specific surface immunoglobulin. We chose surface immunoglobulin specific to CD20 as the molecular target and designed an experiment to evaluate whether CD20 antigen could be incorporated on the viral surface to target cells expressing its cognate CD20 surface immunoglobulin ( Fig. 1) . Immunoglobulins on B-cells are known to endocytose when bound to an antigen, an anti-idiotypic antibody, or an anti-immunoglobulin antibody (Drake et al., 1989) , making them a good target for lentivectors using the intended targeting method. For fusion, we chose the glycoprotein derived from Sindbis virus (denoted as SIN) which has been shown to be able to efficiently pseudotype HIV-1-derived lentiviral vectors. SIN contains two transmembrane proteins (E1, responsible for fusion; E2, responsible for binding), which form a heterodimer when displayed on the viral surface (Phinney et al., 2000) . By making mutations in the E2 protein to inactivate the receptor binding sites, we and other have shown that SIN can be engineered into a This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
binding deficient but fusion functional form (termed SINmu) (Morizono et al., 2005; Yang et al., 2006) .
Preparation of recombinant lentivectors
To produce the recombinant lentivectors, 293T cells were transiently co-transfected using the standard calcium phosphate method (Pear et al., 1993) with the a self-inactivating and replication-incompetent lentiviral backbone that contains a human ubiquitin-C promoter driving the expression of a GFP reporter gene FUGW ( Fig. 2A ) (Lois et al., 2002) , plasmids encoding viral gag, pol, and rev genes, the plasmid encoding human CD20
protein (denoted as pCD20), and the plasmid encoding the fusogenic protein SINmu (denoted as pSINmu). The resultant viral vector from these transfected cells was designated FUGW/CD20+SINmu. Transfection without the plasmid encoding either CD20 or SINmu was performed to generate viral vectors FUGW/SINmu and FUGW/CD20, respectively, which were used as controls. As a positive control we generated a lentivector pseudotyped with VSVG and designated it FUGW/VSVG. Viral producing cells were analyzed three days post-transfection using fluorescence activated cell sorting (FACS) analysis ( Fig. 2B-C) . GFP expression was observed in all transfected cells (Fig. 2B) , indicating the presence of lentiviral backbone in viral producing cells.
When we gated on GFP + cells, we found that approximately 8% of 293T cells coexpressing CD20 and SINmu, which presumably were able to produce FUGW/CD20+SINmu (Fig. 2C ). The apparently low percentage of co-expression is partially due to the insensitivity of anti-CD20 staining antibody, which can only detect highly expressed CD20.
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Co-incorporation of fusogen and binding protein into lentivectors
Since both binding and fusion are required for lentivectors to productively transduce target cells, it is important to investigate if the engineered viral particles express both CD20 and SINmu in a single virion. We designed a confocal imaging experiment to examine this question. We constructed a plasmid that expresses GFP fused to the Nterminus of HIV-1 vpr (designated as GFP-vpr). It has been shown that GFP-vpr was incorporated into the virion when the GFP-vpr plasmid was supplied in trans during viral preparation; the resulting virus was labeled by GFP and could be detected by green fluorescence (McDonald et al., 2002) . We prepared GFP-marked recombinant viral vector FUW-GFPvpr/CD20+SINmu and used a similar transfection condition as used to make FUGW/CD20+SINmu except the lentiviral backbone FUW lacking the GFP transgene replaced FUGW, and an additional plasmid encoding GFP-vpr was utilized.
The resultant viral supernatant was exposed to a clean glass coverslip. Costaining experiments showed that ~40% of GFP-marked viral particles were positive for both CD20 and SINmu (Fig. 3, upper panel) . The colocalization of GFP-vpr, CD20 and SINmu suggests that our method of vector preparation can produce a good fraction of viral particles displaying both binding and fusogenic molecules. We further stained the GFP-vpr-containing particles (FUW-GFPvpr/CD20+SINmu) with an anti-p24 antibody.
It showed that >80% of GFP + particles were p24 + (Fig. 3, lower panel) , suggesting that the dots we detected were the true viral particles. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Binding of viral particles to specific cells
To facilitate our study of specific binding and transduction using engineered lentivectors, we made 293T and Jurkat cell lines expressing CD20 by lentivirus-mediated transduction and cell sorting (293T/ CD20, Fig. 4A&C ; Jurkat/ CD20, Fig. 4B ). FACS analysis showed that the resultant CD20 cell lines had uniform expression of CD20
( Fig. 4A-B) . We compared the human IgG expression level between the cell lines and human peripheral blood mononuclear cells (PBMC) and found that Jurkat/aCD20 expressed a physiologically relevant level of human IgG (lower than the IgG expression in human B cells) (Fig. 4B) . In order to confirm that CD20 displayed on the viral surface is able to maintain its binding specificity, we co-incubated the concentrated viral particles (FUW-GFPvpr/CD20+SINmu) with 293T/ CD20 or 293T cells at 4 o C for one hour. At this temperature, viral particles internalization is reduced. As shown in Figure 4D , GFPmarked virions were detected on the surface of 293T/ CD20, while no detectable virus was seen on the surface of 293T cells. As a control, incubation of either 293T or 293T/ CD20 with viral supernatants harvested from producing cells transfected with plasmids devoid of the plasmid encoding gag/pol resulted in no bound particles.
Addition of soluble anti-CD20 antibody was observed to reduce the number of virions bound to 293T/CD20 cells (data not shown). Thus, CD20 incorporated into the lentiviral particles can retain specific binding to CD20-expressing cells.
Targeted transduction of cell lines in vitro
To test the ability of the engineered recombinant lentivectors to transduce only the cells expressing the selected surface immunoglobulin, the supernatants from the cells transfected to produce FUGW/CD20+SINmu, FUGW/CD20, FUGW/SINmu, or This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. sorting and endosome properties between these two cell lines upon specific binding of FUGW/CD20+SINmu could contribute to different transduction efficiency.
Binding molecule necessary for targeted transduction
To further test if the specific interaction between CD20 on the lentiviral surface and transduction. An isotype control antibody was also used as a negative control. As expected, Figure 5B shows that CD20 antibody concentration negatively correlated with targeted transduction, whereas no correlation was observed between the amount of isotype control antibody and transduction efficiency. Verifying that binding of viral CD20 to cell surface CD20 is necessary for specific transduction.
pH change necessary for targeted transduction
Envelope glycoprotein derived from Sindbis virus is activated by the acidic pH within the lumen of the endosomes to allow fusion of the viral particle to the host cell's endosomal membrane (Glomb-Reinmund and Kielian, 1998) . This fusion allows the viral particle to release its contents into the cell's cytosol. To test if the drop in pH was necessary to trigger SINmu to mediate fusion, we added ammonium chloride (NH 4 Cl) at various concentrations into an incubation mixture of 293T/ CD20 and lentivector This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
FUGW/CD20+SINmu; NH 4 Cl could raise the pH to neutralize the acidic endosomal compartments. Figure 5C shows a significant decrease in transduction with the addition of NH 4 Cl, suggesting that the lentiviral vector displaying a pH-sensitive fusogen SINmu relies on the low pH within the endosome to mediate fusion to achieve targeted transduction.
Targeted transduction in vivo
We used NOD/SCID immunocompromised mice to examine the ability of the engineered lentivector to specifically transduce target cells in vivo. In addition, we also compared the This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
system. For the mice that received the targeting vector FUWLuc/CD20+SINmu, we observed luciferase activity predominately in the area implanted with tumor cells (right side), representing the success of targeted viral vector transduction of tumor cells expressing CD20 in vivo (Fig. 6C, far right) . The mice that received 10 MOI of the targeting virus had a luminescence level on the tumor side that was comparable to that of the mice receiving 50 MOI of non-targeting FUWLuc/VSVG (Fig. 6C) . As compared to FUWLuc/VSVG, the background luminescence on the left bearing no tumor cells was significantly less for targeting vector FUWLuc/CD20+SINmu, indicating a significant specificity of our engineered lentivector.
Targeted suicide gene therapy in vivo
To test the potentially therapeutic role of our targeting system, we used targeting vector to deliver a suicide gene, the Herpes simplex virus type 1 thymidine kinase (HSV1-TK), to xenografted tumors in an immunocompromised mouse model. The cells transduced to express HSV1-TK can be deleted by treatment with the prodrug GCV that is transformed into a toxic metabolite form by HSV1-TK (Blumenthal et al., 2007) . Suicide gene therapy based on HSV1-TK has been evaluated clinically by in situ injection of gammaretroviral vectors to solid tumors (Ram et al., 1997; Satoh et al., 2005) . Targeted delivery of HSV1-TK could potentially improve the safety and efficacy of the therapy. We constructed a lentivector encoding a mutant form of HSV1-TK, termed SR39tk, which has been shown to be more reactive towards the GCV substrate and therefore has enhanced ability to kill tumor cells (Black et al., 2001) . The resulting vector is designated FUWSR39tk (Fig. 7A) . The tumor cells bearing surface CD20 (Jurkat/ CD20) were This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. control. From day 7 to day 12, select mice were treated with an intraperitonial injection of 50 mg/kg of the prodrug GCV daily. Mice were imaged throughout the process to chart the effect of each step on tumor growth (Fig. 7C-D) . Growth of the tumor before GCV treatment appeared to be unaltered by the transduction of the tumor cells with the SR39tk-expressing lentivector, as similar tumor growth was observed between the mice injected with FUWSR39tk/CD20+SINmu and the mice that received no viral vector (Fig.   7D ). The GCV treatment alone initially slowed the growth of the tumor, but normal growth rate was retained after the completion of the 5-day GCV treatment (Fig. 7C-D) .
The largest effect could be seen on the mice that were injected with the targeting lentivector FUWSR39tk/CD20+SINmu or the non-targeted FUWSR39tk/VSVG and the prodrug GCV. In these mice, the tumor growth appeared to be efficiently suppressed for more than three weeks, as can be seen in Figure 7C -D.
Discussion
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Our results demonstrate that recombinant lentivector can be engineered to target cells expressing an antigen-specific immunoglobulin in vitro and in vivo. The general targeting strategy is to display an antigen protein and a fusogenic protein on the lentiviral surface. In the model system we reported here, the antigen protein is CD20, which is the specific antigen for the surface immunoglobulin CD20, and the fusogenic protein is SINmu, which is a binding-deficient and fusion-competent envelope protein derived from This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
carrying either CD20 or SINmu resulted in no transduction, the lentivector bearing both CD20 and SINmu can efficiently transduce 293T/ CD20 cells (79.5%). We further showed in vivo targeted transduction of a xenografted Jurkat/ CD20 tumor.
Jurkat/ CD20 was injected subcutaneously into the right flank of This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
is a feasible approach to targeting clonal and autoreactive B-cells for certain autoimmune diseases with known antigens such as pemphigus vulgaris and Graves' disease (Davidson and Diamond, 2001 ). For the cases in which the antigen against a specific immunoglobulin is unknown, we can use the previously reported method (Yang et al., 2006) to incorporate a secondary, anti-idiotypic antibody onto the lentiviral surface.
Thus, these two methods could complement each other to provide novel ways to achieve gene delivery to defined populations of B-cells.
Delivery of modulating genes to antigen-specific B-cells could be used to tune Bcell function related to a particular antigen. For example, class switching and differentiation of B-cells can vary depending upon the available cytokine concentration (Tarlinton, 2006) . Interleukin (IL)-4 plays important roles in driving the switch to IgG1 and further to IgE (Snapper et al., 1988) . Cytokines, such as IL-2, IL-5 and transforming growth factor (TGF)-, could alter B-cells to augment their production of specific IgA This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. (Chaiwatanatorn et al., 2003; Imashuku et al., 2004) and increased susceptibility to infection (Wadhwa and Morrison, 2006) . Targeting a more specific population of B-cells with a suicide gene therapy could overcome some of the challenges that Rituximab faces.
To test if our system could effectively deliver a suicide gene in vivo, we set up a mouse model with a xenografted tumor expressing firefly luciferase. By measuring the bioluminescence from firefly luciferase, we can monitor the kinetic growth of the tumor.
We found that a single dose injection of FUWSR39tk/CD20+SINmu along with the prodrug treatment is able to substantially suppress tumor growth. Although we clearly
showed that more cells were targeted by using the targeting vector (Fig. 6C) , we did not observe markedly improved suppression of tumor growth by using the targeting vector as opposed to the non-targeting vector (Fig. 7C-D) . One possible explanation is the known bystander effect of suicide gene therapy (Freeman et al., 1993) . Although only a small fraction of the tumor cells were transduced to express the suicide gene, Freeman et al.
remained to be able to detect a significant reduction in tumor size after GCV treatment (Freeman et al., 1993) . The increase of the dose and frequency of injection of targeting lentivector bearing the suicide gene could further enhance the efficiency of tumor therapy.
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Recently a clinical trial using lentivectors to deliver antisense RNA for anti-HIV therapy has shown no detectable adverse effects (Levine et al., 2006) , highlighting the promise of lentivectors for gene therapy (Kohn, 2007) . (Blumenthal et al., 2007) .
Our findings suggest that engineering a gene delivery system based on lentivectors to target antigen-specific immunoglobulin-expressing cells is feasible both in vitro and in vivo using direct intratumoral injection. It should be pointed out that such an approach may be appropriate for clinically colocalized disease, such as low stage nonHodgkin lymphoma. Future work will be required to validate this method for systemic administration of lentivectors for disseminated disease.
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